Iranian Journal of Medical Sciences

Iranian Journal of Medical Sciences

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Journal Team

Publication Ethics

Indexing and Abstracting

Related Links

Peer Review Process

Journal Metrics

Associations between Chinese Visceral Adiposity Index and the Risk of Steatotic Liver Disease and Liver Fibrosis Related to Metabolic Dysfunction: A Large Cross-sectional Study

Articles InPress

Document Type : Original Article(s)

Authors

1 Department of Emergency Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

2 Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

3 Department of Geriatrics, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

10.30476/ijms.2024.100818.3335

Abstract

Background: The associations between Chinese visceral adiposity index (CVAI) and non-alcoholic fatty liver disease (NAFLD) or hepatic fibrosis in Westerners are not obvious. Furthermore, metabolic dysfunction-associated steatotic liver disease (MASLD) is the new nomenclature of NAFLD, with significantly different diagnostic criteria. The present study aimed to investigate the relationships between CVAI and MASLD or hepatic fibrosis in an American population, as well as to assess the diagnostic value of CVAI for MASLD and fibrosis.
Methods: After excluding missing data on calculations of indices, diagnosis of MASLD, and covariates, 3242 participants were selected from the National Health and Nutrition Examination Survey 2017-2020. Multivariate logistic regression analyses and restricted cubic spline (RCS) were used to determine the associations between CVAI and MASLD or fibrosis. The diagnostic capacity was evaluated by the area under the receiver operating characteristic (AUROC) curve. Data were analyzed using R software (version 4.2.2). P<0.05 was considered statistically significant. 
Results: The risk of MASLD was increased at quartiles 2, 3, and 4 compared with quartile 1 of CVAI (OR [95% CI]=3.66 [2.44-5.63], 7.954 [5.31-12.23], and 14.84 [9.80-23.06], respectively), (P<0.001). The odds ratios (95% CI) of hepatic fibrosis risk were 1.23 [0.67, 2.30], 2.44 [1.39, 4.43], 7.46 [4.36, 13.30] for the quartiles 2, 3, and 4 compared to the lowest quartile (P<0.001). According to RCS, CVAI, MASLD, and fibrosis, all had positive relationships. CVAI had AUROCs of 0.759 and 0.771 for diagnosing MASLD and fibrosis, respectively. 
Conclusion: The CVAI was positively related to the risk of MASLD or liver fibrosis and could be a novel biomarker for predicting MASLD and fibrosis in the American population.

Keywords

References
  1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212-24. doi: 10.1016/S0140-6736(20)32511-3. PubMed PMID: 33894145.
  2. Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. Biomedicines. 2021;9. doi: 10.3390/biomedicines9121890. PubMed PMID: 34944706; PubMed Central PMCID: PMCPMC8698356.
  3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep.28431. PubMed PMID: 26707365.
  4. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-76. doi: 10.1007/s00535-017-1415-1. PubMed PMID: 29247356; PubMed Central PMCID: PMCPMC5847174.
  5. Ciardullo S, Monti T, Perseghin G. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2021;19:384-90. doi: 10.1016/j.cgh.2020.06.048. PubMed PMID: 32623006.
  6. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97. doi: 10.1016/j.metabol.2018.11.014. PubMed PMID: 30502373.
  7. Chen X, Shi F, Xiao J, Huang F, Cheng F, Wang L, et al. Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index. Front Endocrinol (Lausanne). 2022;13:831960. doi: 10.3389/fendo.2022.831960. PubMed PMID: 35360076; PubMed Central PMCID: PMCPMC8960385.
  8. Xia MF, Chen Y, Lin HD, Ma H, Li XM, Aleteng Q, et al. A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese. Sci Rep. 2016;6:38214. doi: 10.1038/srep38214. PubMed PMID: 27905531; PubMed Central PMCID: PMCPMC5131270.
  9. Han M, Qin P, Li Q, Qie R, Liu L, Zhao Y, et al. Chinese visceral adiposity index: A reliable indicator of visceral fat function associated with risk of type 2 diabetes. Diabetes Metab Res Rev. 2021;37:e3370. doi: 10.1002/dmrr.3370. PubMed PMID: 32562335.
  10. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202-9. doi: 10.1016/j.jhep.2020.03.039. PubMed PMID: 32278004.
  11. Tang M, Wei XH, Cao H, Zhen Q, Liu F, Wang YF, et al. Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:935980. doi: 10.3389/fendo.2022.935980. PubMed PMID: 35979441; PubMed Central PMCID: PMCPMC9376620.
  12. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133. doi: 10.1016/j.aohep.2023.101133. PubMed PMID: 37364816.
  13. Liu J, Tan L, Liu Z, Shi R. The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018. Ann Med. 2022;54:2259-68. doi: 10.1080/07853890.2022.2110277. PubMed PMID: 35975984; PubMed Central PMCID: PMCPMC9455329.
  14. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953-2041. doi: 10.1097/HJH.0000000000001940. PubMed PMID: 30234752.
  15. American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:S14-S31. doi: 10.2337/dc20-S002. PubMed PMID: 31862745.
  16. Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-81 e4. doi: 10.1053/j.gastro.2018.12.036. PubMed PMID: 30660725; PubMed Central PMCID: PMCPMC7505052.
  17. Ciardullo S, Muraca E, Zerbini F, Manzoni G, Perseghin G. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. J Clin Endocrinol Metab. 2021;106:e2856-e65. doi: 10.1210/clinem/dgab262. PubMed PMID: 33878156.
  18. Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41:1290-3. doi: 10.1111/liv.14828. PubMed PMID: 33590934.
  19. Park BJ, Kim YJ, Kim DH, Kim W, Jung YJ, Yoon JH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol. 2008;23:900-7. doi: 10.1111/j.1440-1746.2007.05212.x. PubMed PMID: 17995942.
  20. Ali-Eldin ZA, Ali-Eldin FA, Mohamed IE. Visceral Adiposity Index and the Degree of Hepatic Fibrosis and Inflammation in Egyptian Patients with Chronic Hepatitis C. J Clin Diagn Res. 2017;11:OC11-OC4. doi: 10.7860/JCDR/2017/28381.10330. PubMed PMID: 28969177; PubMed Central PMCID: PMCPMC5620818.
  21. Petta S, Amato MC, Di Marco V, Camma C, Pizzolanti G, Barcellona MR, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:238-47. doi: 10.1111/j.1365-2036.2011.04929.x. PubMed PMID: 22117531.
  22. Ha NB, Cho SJ, Mohamad Y, Kent D, Jun G, Wong R, et al. Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis. Dig Dis Sci. 2022;67:3436-44. doi: 10.1007/s10620-021-07099-8. PubMed PMID: 34136974; PubMed Central PMCID: PMCPMC8815298.
  23. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449-57. doi: 10.1002/hep.22350. PubMed PMID: 18627003.
  24. Ooi GJ, Burton PR, Bayliss J, Raajendiran A, Earnest A, Laurie C, et al. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. Obes Surg. 2019;29:99-108. doi: 10.1007/s11695-018-3479-2. PubMed PMID: 30229460.
  25. Han M, Qie R, Li Q, Liu L, Huang S, Wu X, et al. Chinese visceral adiposity index, a novel indicator of visceral obesity for assessing the risk of incident hypertension in a prospective cohort study. Br J Nutr. 2021;126:612-20. doi: 10.1017/S0007114520004298. PubMed PMID: 33143773.
  26. Xie X, Li Q, Zhang L, Ren W. Lipid Accumulation Product, Visceral Adiposity Index, and Chinese Visceral Adiposity Index as Markers of Cardiometabolic Risk in Adult Growth Hormone Deficiency Patients: A Cross-Sectional Study. Endocr Pract. 2018;24:33-9. doi: 10.4158/EP-2017-0007. PubMed PMID: 29144802.
  27. Zhao Y, He Y, Zhang L, Liu J, Bai Y, Wang M, et al. Effect of CVAI on the incidence of MASLD compared to BMI in populations with different body types: A prospective cohort study in China. Nutr Metab Cardiovasc Dis. 2024;34:307-16. doi: 10.1016/j.numecd.2023.09.009. PubMed PMID: 37949714.
  28. Chen L, Tao X, Zeng M, Mi Y, Xu L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024;80:e64-e6. doi: 10.1016/j.jhep.2023.08.021. PubMed PMID: 37714381.
  29. Lu Y, Ge L, Yang H, He Y, Wang Y. Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women. Diabetes Metab Syndr Obes. 2023;16:607-17. doi: 10.2147/DMSO.S402814. PubMed PMID: 36909348; PubMed Central PMCID: PMCPMC9999715.
  30. Shen S, Huang H, Wang J, Tang Z, Shen C, Xu C. Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults. Dig Dis Sci. 2023;68:656-64. doi: 10.1007/s10620-022-07787-z. PubMed PMID: 36512267.
  31. Li R, Liu J, Han P, Shi R, Zhao L, Li J. Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index. J Gastroenterol Hepatol. 2023;38:1316-24. doi: 10.1111/jgh.16196. PubMed PMID: 37102199.
  32. Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-64. doi: 10.1002/hep.31150. PubMed PMID: 32012320.
  33. Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio. Eur J Clin Nutr. 2010;64:2-5. doi: 10.1038/ejcn.2009.139. PubMed PMID: 19935820.
  34. Camhi SM, Bray GA, Bouchard C, Greenway FL, Johnson WD, Newton RL, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring). 2011;19:402-8. doi: 10.1038/oby.2010.248. PubMed PMID: 20948514; PubMed Central PMCID: PMCPMC3960785.
  35. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911-8. doi: 10.1111/j.1478-3231.2012.02820.x. PubMed PMID: 22672642.
  36. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1717-30. doi: 10.1053/j.gastro.2019.01.042. PubMed PMID: 30689971.
Iranian Journal of Medical Sciences

Articles InPress, Corrected Proof
Available Online from 23 October 2024
Files
History
  • Received: 18 November 2023
  • Revised: 11 January 2024
  • Accepted: 20 February 2024
Share
How to cite
Statistics